{
  "object_id": "revive:rosuvastatin-5mg",
  "object_type": "Dose Decision Object",
  "schema_version": "1.0",
  "language": "en",
  "canonical_url": "/rosuvastatin-5mg/",
  "canonical_page_h1": "Rosuvastatin 5mg: Statin Dose Decision Guide",
  "entity_slug": "rosuvastatin-5mg",
  "primary_entity": "rosuvastatin",
  "entity_family": "Statins / Lipids",
  "page_kind": "dose",
  "decision_stage": "BOFU / decision",
  "ymyl": true,
  "source_phase": "Phase 2 Answer-First Citation Blocks",
  "decision_dimensions": [
    "dose_role",
    "effectiveness",
    "response",
    "tolerability",
    "escalation",
    "deescalation",
    "monitoring",
    "interactions",
    "comorbidity",
    "adherence",
    "switching",
    "comparison",
    "safety",
    "patient_context",
    "natural_language",
    "summary"
  ],
  "answers": [
    {
      "query_id": "RZQ-01921",
      "question": "What does rosuvastatin 5 mg mean in the drug's overall dosing range?",
      "short_answer": "Rosuvastatin 5 mg belongs to the rosuvastatin dose range and should not be converted into a milligram-for-milligram comparison with atorvastatin or another statin. The clinically relevant issue is whether this exact rosuvastatin strength is producing the intended lipid response for the person’s treatment plan. The best way to interpret rosuvastatin 5 mg is to consider LDL response and tolerability at the same time.",
      "citations": [
        {
          "label": "MedlinePlus drug information: Rosuvastatin",
          "url": "https://medlineplus.gov/druginfo/meds/a603033.html"
        },
        {
          "label": "DailyMed current human drug-label search: Rosuvastatin",
          "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=human&query=rosuvastatin"
        },
        {
          "label": "Clinical guideline context: ACC/AHA 2026 Dyslipidemia Guideline",
          "url": "https://www.acc.org/latest-in-cardiology/journal-scans/2026/03/13/15/20/acc-aha-release-new-clinical-guideline-for-managing-dyslipidemia"
        }
      ]
    },
    {
      "query_id": "RZQ-01922",
      "question": "Why might rosuvastatin 5 mg be chosen instead of a lower or higher strength?",
      "short_answer": "The best way to interpret rosuvastatin 5 mg is to consider LDL response and tolerability at the same time. If lipid goals are being met and the regimen is comfortable to continue, the existence of a higher strength does not create a reason to escalate. If the response is incomplete, the cause of that shortfall should be defined before changing the dose.",
      "citations": [
        {
          "label": "MedlinePlus drug information: Rosuvastatin",
          "url": "https://medlineplus.gov/druginfo/meds/a603033.html"
        },
        {
          "label": "DailyMed current human drug-label search: Rosuvastatin",
          "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=human&query=rosuvastatin"
        },
        {
          "label": "Clinical guideline context: ACC/AHA 2026 Dyslipidemia Guideline",
          "url": "https://www.acc.org/latest-in-cardiology/journal-scans/2026/03/13/15/20/acc-aha-release-new-clinical-guideline-for-managing-dyslipidemia"
        }
      ]
    },
    {
      "query_id": "RZQ-01923",
      "question": "Is rosuvastatin 5 mg usually a starting, middle, or upper-range dose decision?",
      "short_answer": "Rosuvastatin 5 mg belongs to the rosuvastatin dose range and should not be converted into a milligram-for-milligram comparison with atorvastatin or another statin. The clinically relevant issue is whether this exact rosuvastatin strength is producing the intended lipid response for the person’s treatment plan. The best way to interpret rosuvastatin 5 mg is to consider LDL response and tolerability at the same time.",
      "citations": [
        {
          "label": "MedlinePlus drug information: Rosuvastatin",
          "url": "https://medlineplus.gov/druginfo/meds/a603033.html"
        },
        {
          "label": "DailyMed current human drug-label search: Rosuvastatin",
          "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=human&query=rosuvastatin"
        },
        {
          "label": "Clinical guideline context: ACC/AHA 2026 Dyslipidemia Guideline",
          "url": "https://www.acc.org/latest-in-cardiology/journal-scans/2026/03/13/15/20/acc-aha-release-new-clinical-guideline-for-managing-dyslipidemia"
        }
      ]
    }
  ],
  "related_questions": [
    {
      "query_id": "RZQ-01921",
      "question": "What does rosuvastatin 5 mg mean in the drug's overall dosing range?",
      "priority": "P1",
      "micro_intent": "dose_role"
    },
    {
      "query_id": "RZQ-01922",
      "question": "Why might rosuvastatin 5 mg be chosen instead of a lower or higher strength?",
      "priority": "P1",
      "micro_intent": "dose_role"
    },
    {
      "query_id": "RZQ-01923",
      "question": "Is rosuvastatin 5 mg usually a starting, middle, or upper-range dose decision?",
      "priority": "P1",
      "micro_intent": "dose_role"
    },
    {
      "query_id": "RZQ-01924",
      "question": "What should someone expect to evaluate after using rosuvastatin 5 mg?",
      "priority": "P2",
      "micro_intent": "effectiveness"
    },
    {
      "query_id": "RZQ-01925",
      "question": "If rosuvastatin 5 mg is not working well enough, does that automatically mean the dose should be increased?",
      "priority": "P2",
      "micro_intent": "response"
    },
    {
      "query_id": "RZQ-01926",
      "question": "How can someone tell whether rosuvastatin 5 mg is doing what it is supposed to do?",
      "priority": "P2",
      "micro_intent": "response"
    },
    {
      "query_id": "RZQ-01927",
      "question": "What side effects would make rosuvastatin 5 mg worth reviewing?",
      "priority": "P2",
      "micro_intent": "tolerability"
    },
    {
      "query_id": "RZQ-01928",
      "question": "When can a lower dose than rosuvastatin 5 mg become a reasonable discussion?",
      "priority": "P2",
      "micro_intent": "tolerability"
    },
    {
      "query_id": "RZQ-01929",
      "question": "What evidence would justify moving above rosuvastatin 5 mg?",
      "priority": "P2",
      "micro_intent": "escalation"
    },
    {
      "query_id": "RZQ-01930",
      "question": "What evidence would justify stepping down from rosuvastatin 5 mg?",
      "priority": "P2",
      "micro_intent": "deescalation"
    },
    {
      "query_id": "RZQ-01931",
      "question": "What monitoring matters after starting or changing to rosuvastatin 5 mg?",
      "priority": "P2",
      "micro_intent": "monitoring"
    },
    {
      "query_id": "RZQ-01932",
      "question": "Can other medicines change how rosuvastatin 5 mg should be evaluated?",
      "priority": "P2",
      "micro_intent": "interactions"
    },
    {
      "query_id": "RZQ-01933",
      "question": "How can kidney, liver, heart, or vascular conditions affect the decision around rosuvastatin 5 mg?",
      "priority": "P2",
      "micro_intent": "comorbidity"
    },
    {
      "query_id": "RZQ-01934",
      "question": "Could timing or missed doses make rosuvastatin 5 mg look ineffective?",
      "priority": "P2",
      "micro_intent": "adherence"
    },
    {
      "query_id": "RZQ-01935",
      "question": "When should someone consider changing the drug instead of changing rosuvastatin 5 mg?",
      "priority": "P2",
      "micro_intent": "switching"
    },
    {
      "query_id": "RZQ-01936",
      "question": "How is rosuvastatin 5 mg different from the nearest lower strength?",
      "priority": "P2",
      "micro_intent": "comparison"
    },
    {
      "query_id": "RZQ-01937",
      "question": "How is rosuvastatin 5 mg different from the nearest higher strength?",
      "priority": "P2",
      "micro_intent": "comparison"
    },
    {
      "query_id": "RZQ-01938",
      "question": "What are the main safety questions to ask before changing rosuvastatin 5 mg?",
      "priority": "P2",
      "micro_intent": "safety"
    },
    {
      "query_id": "RZQ-01939",
      "question": "What if rosuvastatin 5 mg works but causes side effects?",
      "priority": "P2",
      "micro_intent": "patient_context"
    },
    {
      "query_id": "RZQ-01940",
      "question": "What if rosuvastatin 5 mg is tolerated but the treatment goal is not reached?",
      "priority": "P2",
      "micro_intent": "patient_context"
    },
    {
      "query_id": "RZQ-01941",
      "question": "I am taking rosuvastatin 5 mg. What should I track before asking for a dose change?",
      "priority": "P2",
      "micro_intent": "natural_language"
    },
    {
      "query_id": "RZQ-01942",
      "question": "My doctor mentioned rosuvastatin 5 mg. What questions should I ask before changing doses?",
      "priority": "P2",
      "micro_intent": "natural_language"
    },
    {
      "query_id": "RZQ-01943",
      "question": "How do I know whether the problem is the dose or the medication itself with rosuvastatin 5 mg?",
      "priority": "P2",
      "micro_intent": "natural_language"
    },
    {
      "query_id": "RZQ-01944",
      "question": "What is the most important decision logic around rosuvastatin 5 mg?",
      "priority": "P2",
      "micro_intent": "summary"
    }
  ],
  "evidence": [
    {
      "label": "MedlinePlus drug information: Rosuvastatin",
      "url": "https://medlineplus.gov/druginfo/meds/a603033.html"
    },
    {
      "label": "DailyMed current human drug-label search: Rosuvastatin",
      "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=human&query=rosuvastatin"
    },
    {
      "label": "Clinical guideline context: ACC/AHA 2026 Dyslipidemia Guideline",
      "url": "https://www.acc.org/latest-in-cardiology/journal-scans/2026/03/13/15/20/acc-aha-release-new-clinical-guideline-for-managing-dyslipidemia"
    }
  ],
  "review": {
    "visible_page_review_date": null,
    "object_generated_date": "2026-09-11",
    "claim_level_confidence": "not_assigned",
    "confidence_note": "This object preserves answer text and citations already present on the canonical page. Claim-level confidence scoring and source-provenance grading are deferred to the later evidence/provenance phase."
  },
  "safety": {
    "educational_only": true,
    "not_individual_prescribing_advice": true,
    "do_not_stop_or_change_prescription_without_clinician_review": true
  },
  "implementation": {
    "preferred_rendering": "answer-first blocks + machine-readable JSON",
    "new_url_required": false,
    "canonical_page_remains_primary": true
  }
}